TYSABRI
Biological
Biogen, Inc.
Total Payments
$44.4M
Transactions
138,972
Doctors
9,573
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1.3M | 9,998 | 2,858 |
| 2023 | $466,004 | 14,365 | 3,766 |
| 2022 | $3.7M | 18,533 | 3,846 |
| 2021 | $5.3M | 17,109 | 3,757 |
| 2020 | $10.1M | 8,238 | 2,099 |
| 2019 | $11.3M | 18,307 | 3,547 |
| 2018 | $7.2M | 26,063 | 3,494 |
| 2017 | $5.0M | 26,359 | 3,492 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $25.0M | 2,771 | 56.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $10.1M | 3,532 | 22.7% |
| Consulting Fee | $5.6M | 2,977 | 12.6% |
| Food and Beverage | $2.4M | 122,891 | 5.4% |
| Travel and Lodging | $1.3M | 5,289 | 2.9% |
| Education | $57,436 | 1,512 | 0.1% |
Payments by Type
Research
$25.0M
2,771 transactions
General
$19.4M
136,201 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration | Biogen, Inc. | $7.6M | 0 |
| A Study to Evaluate Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing of Natalizumab (BG00002) in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) Switching From Treatment With 4-Week Natalizumab Standard Interval Dosing (SID) in Relation to Continued SID Treatment | Biogen, Inc. | $5.1M | 0 |
| Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy | Biogen, Inc. | $3.6M | 25 |
| Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants | Biogen, Inc. | $1.5M | 0 |
| Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke | Biogen, Inc. | $1.3M | 3 |
| A Randomized, Controlled, Open-Label, Rater-Blinded, Phase 3b Study of the Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing of Natalizumab (BG00002) in Subjects With Relapsing-Remitting Multiple SclerosisSwitching From Treatment With 4-Week Natalizumab Standard Interval Dosing (SID) in Relation to Continued SID Treatment | Biogen, Inc. | $1.0M | 0 |
| Natalizumab for use in Patients with High Risk Graft Versus Host Disease (GVHD) | Biogen, Inc. | $919,119 | 0 |
| US-TYS-14-10669- Natalizumab for use in Patients with High Risk Graft Versus Host Disease (GVHD) | Biogen, Inc. | $611,820 | 0 |
| EID Columbia and NYU SRA | Biogen, Inc. | $274,866 | 0 |
| Comparison of Tysabri, Vumerity, and Ocrevus in MS Patients Stable on Therapy to Characterize Divergent Proteomic, Radiomic, and Clinical Trajectories | Biogen, Inc. | $255,129 | 0 |
| US-TYS-18-11393 (Foley): Evaluation of Extended Interval Dosing of Natalizumab Efficacy: Retrospective MRI Review (AOP 19-164) | Biogen, Inc. | $242,760 | 0 |
| Single-center retrospective safety analysis of multiple sclerosis patients treated with high efficacy disease modifying therapies | Biogen, Inc. | $222,539 | 0 |
| Phase I/II Study of the Use of Tysabri in the Treatment of Graft-vs-Host Disease | Biogen, Inc. | $204,000 | 0 |
| Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) - TOUCH Data Linkage Sub-study | Biogen, Inc. | $174,330 | 0 |
| Long-term outcomes of multiple sclerosis patients on extended interval dosing of Natalizumab | Biogen, Inc. | $172,417 | 0 |
| Does Long Term Natalizumab Therapy Normalize Brain Atrophy Rates and QOL in RRMS? (A Longitudinal Study Using Whole Brain, Neocortical and Subcortical, Atrophy Rates and Patient Reported Outcomes) | Biogen, Inc. | $151,459 | 0 |
| EXTENDED INTERVAL DOSING SCHEDULES FOR NATALIZUMAB: RETROSPECTIVE REGISTRIES | Biogen, Inc. | $139,847 | 0 |
| US-TYS-18-11394 - Evaluation of Extended Interval Dosing of Natalizumab Efficacy: Retrospective MRI Review | Biogen, Inc. | $137,946 | 0 |
| Real-world experience of using Tysabri in 750 MS patients over 15 years in a single US center in the absence of PML - focusing on unique clinical practice in evolution of risk mitigating strategies. | Biogen, Inc. | $115,215 | 1 |
| Single Tysabri Infusion for Anterior Ischemic Optic Neuropathies and Central Retinal Artery Occlusions Caused by Giant Cell Arteritis | Biogen, Inc. | $89,941 | 0 |
Top Doctors Receiving Payments for TYSABRI
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Jason King | — | Oklahoma City, OK | $24.7M | 2,581 |
| , MD | Neurology | Los Angeles, CA | $488,849 | 524 |
| , MD | Neurology | Vienna, VA | $426,938 | 690 |
| , DO | Neurology | Dublin, OH | $382,765 | 434 |
| , M.D | Neurology | Milwaukee, WI | $359,474 | 206 |
| , M.D | Neurology | Newport Beach, CA | $253,128 | 298 |
| , M.D | Specialist | Guaynabo, PR | $191,626 | 378 |
| , M.D | Neurology | Chicago, IL | $187,244 | 118 |
| , MD | Neurology | Amarillo, TX | $183,069 | 267 |
| , M.D | Neurology | Cincinnati, OH | $173,097 | 147 |
| , MD | Neurology | Albuquerque, NM | $165,970 | 155 |
| , MD | Neurology | Santa Barbara, CA | $164,725 | 165 |
| , M.D | Neurology | Tampa, FL | $152,954 | 211 |
| , M.D | Neurology | Salt Lake Cty, UT | $150,637 | 279 |
| Douglas Jeffery | — | Huntersville, NC | $141,899 | 187 |
| , MD | Neurology | Phoenix, AZ | $138,681 | 173 |
| , M.D | Neurology | Reno, NV | $138,445 | 202 |
| , M.D | Neurology | Winchester, VA | $135,753 | 414 |
| , M.D | Neurology | Bethpage, NY | $129,380 | 136 |
| , MD | Neurology | Knoxville, TN | $127,771 | 171 |
| , M.D | Neurology | Staten Island, NY | $126,550 | 227 |
| Peter Wade | — | Hartford, CT | $125,992 | 160 |
| , MD | Specialist | Carrollton, VA | $123,437 | 158 |
| , M.D. PH.D | Neurology | Round Rock, TX | $118,078 | 113 |
| , M.D | Neurology | Overland Park, KS | $116,503 | 318 |
Ad
Manufacturing Companies
- Biogen, Inc. $44.4M
Product Information
- Type Biological
- Total Payments $44.4M
- Total Doctors 9,573
- Transactions 138,972
About TYSABRI
TYSABRI is a biological associated with $44.4M in payments to 9,573 healthcare providers, recorded across 138,972 transactions in the CMS Open Payments database. The primary manufacturer is Biogen, Inc..
Payment data is available from 2017 to 2024. In 2024, $1.3M was paid across 9,998 transactions to 2,858 doctors.
The most common payment nature for TYSABRI is "Unspecified" ($25.0M, 56.3% of total).
TYSABRI is associated with 20 research studies, including "A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration" ($7.6M).